Ticagrelor

Ticagrelor, also known by the brand names Brilinta, Brilique, and Possia, is an antiplatelet medication that has been the subject of numerous clinical trials. These studies aim to evaluate its safety, efficacy, and pharmacokinetics in different patient populations, including those with acute coronary syndrome, renal impairment, and undergoing percutaneous coronary intervention. The trials explore various aspects of Ticagrelor use, such as dosing strategies, administration methods, and comparison with other antiplatelet drugs.

Table of Contents

What is Ticagrelor?

Ticagrelor is a medication used to prevent blood clots in patients with certain heart conditions. It is known by several brand names, including Brilinta, Brilique, and Possia[1]. In some countries, generic versions of ticagrelor are also available, such as Ticaloguard[2]. Ticagrelor belongs to a class of drugs called P2Y12 inhibitors, which work by preventing platelets (small blood cells that help with clotting) from sticking together and forming clots[3].

How Ticagrelor Works

Ticagrelor works by blocking a specific receptor on platelets called P2Y12. By doing this, it prevents platelets from clumping together and forming blood clots. This action is particularly important for patients who have had heart attacks or are at risk of developing blood clots in their heart or blood vessels[4].

When you take ticagrelor, it is absorbed into your bloodstream and starts working to inhibit platelet function. The medication has an active metabolite (a substance produced when your body processes the drug) called AR-C124910XX, which also contributes to its antiplatelet effect[5].

Conditions Treated with Ticagrelor

Ticagrelor is primarily used to treat and prevent complications in patients with:

  • Acute Coronary Syndrome (ACS): This is an umbrella term for conditions where the blood supply to the heart is suddenly blocked or reduced. It includes:
    • Heart attacks (myocardial infarction)
    • Unstable angina (chest pain that occurs at rest or with minimal exertion)
  • Ischemic Stroke: A type of stroke caused by a blood clot blocking a blood vessel in the brain
  • Transient Ischemic Attack (TIA): Often called a “mini-stroke,” this is a temporary blockage of blood flow to the brain
  • Coronary Artery Disease: A condition where the arteries that supply blood to the heart become narrowed or blocked

Ticagrelor is often prescribed to patients who have undergone procedures such as percutaneous coronary intervention (PCI) or stent placement to help prevent blood clots from forming in the newly opened or stented arteries[6].

Dosage and Administration

Ticagrelor is typically taken orally in tablet form. The usual dosing regimen includes:

  • Loading dose: 180 mg (usually given as two 90 mg tablets) at the start of treatment
  • Maintenance dose: 90 mg twice daily

It’s important to note that the exact dosage may vary depending on your specific condition and other factors. Always follow your doctor’s instructions regarding dosage[7].

Interestingly, some studies have explored different ways of taking ticagrelor to potentially improve its effectiveness. For example, one study looked at whether chewing the tablet before swallowing could lead to faster drug absorption and quicker antiplatelet effects compared to swallowing the tablet whole[1].

Effectiveness of Ticagrelor

Ticagrelor has been shown to be effective in reducing the risk of cardiovascular events in patients with acute coronary syndrome. Clinical trials have demonstrated that it can lower the chances of having another heart attack, stroke, or dying from cardiovascular causes[6].

The effectiveness of ticagrelor is typically measured by its ability to inhibit platelet function. This is often assessed using specialized blood tests that measure how well platelets can aggregate (clump together) in response to certain chemicals. A higher level of platelet inhibition generally indicates that the medication is working effectively to prevent blood clots[2].

Potential Side Effects

Like all medications, ticagrelor can cause side effects. Some of the most common include:

  • Bleeding: Because ticagrelor affects blood clotting, it can increase the risk of bleeding. This can range from minor bleeding (like nosebleeds or easy bruising) to more serious bleeding events.
  • Shortness of breath: Some patients may experience difficulty breathing, especially during the first few weeks of treatment.
  • Headache
  • Nausea

It’s important to report any unusual symptoms or side effects to your healthcare provider[6].

Special Considerations

There are some special considerations to keep in mind when taking ticagrelor:

  • Kidney function: If you have kidney problems, your doctor may need to adjust your dosage or monitor you more closely. Studies have been conducted to understand how ticagrelor works in patients with severe kidney disease, including those on hemodialysis[5].
  • Surgery: If you need to have surgery, your doctor may advise you to stop taking ticagrelor for a short period before the procedure to reduce the risk of excessive bleeding.
  • Other medications: Ticagrelor can interact with other drugs, so it’s important to tell your doctor about all medications you’re taking, including over-the-counter drugs and supplements.
  • Pregnancy and breastfeeding: If you’re pregnant, planning to become pregnant, or breastfeeding, discuss the potential risks and benefits of ticagrelor with your healthcare provider.

Remember, ticagrelor is a powerful medication that can significantly reduce your risk of heart attacks and strokes, but it’s important to take it exactly as prescribed and to maintain regular follow-ups with your healthcare provider[7].

Aspect Details
Drug Name Ticagrelor (also known as AZD6140, Brilinta, Brilique, Possia)
Drug Class Antiplatelet medication (P2Y12 receptor inhibitor)
Main Indications Acute Coronary Syndrome, Percutaneous Coronary Intervention
Dosing Strategies Standard dose: 90 mg twice daily
Lower dose: 45 mg twice daily
Loading dose: 180 mg
Patient Populations Acute Coronary Syndrome patients, Renal Impairment patients, Healthy volunteers, Chinese and Japanese populations
Primary Outcomes Pharmacokinetics, Pharmacodynamics, Platelet inhibition, Major Adverse Cardiovascular Events, Bleeding events
Administration Methods Oral tablets (integral and chewed)
Comparison Studies Generic vs. Brand-name, Different dosing strategies, Timing of administration relative to procedures

Ongoing Clinical Trials on Ticagrelor

  • Study on the Safety and Effectiveness of Short Dual Antiplatelet Therapy with Ticagrelor, Clopidogrel, and Prasugrel in Patients Aged 65+ with Coronary Artery Disease

    Recruiting

    1 1 1 1
    Investigated diseases:
    France
  • Study on Preventing Blood Clots in Patients with New-Onset Post-Operative Atrial Fibrillation after CABG Using Apixaban and Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Germany
  • Study on the Effects of Ticagrelor and Rivaroxaban in Patients with Atrial Fibrillation After Coronary Stent Surgery

    Recruiting

    1 1 1 1
    Belgium France Germany Italy The Netherlands Poland +1
  • Study on the Effects of Ticagrelor and Acetylsalicylic Acid in Patients with Coronary Artery Disease Undergoing CABG Surgery

    Recruiting

    1 1 1 1
    Investigated diseases:
    Austria Germany Sweden
  • Study on the Effectiveness of Clopidogrel, Prasugrel, and Ticagrelor in Patients with Coronary Acute Syndrome Using VerifyNow Device

    Recruiting

    1 1 1 1
    Investigated diseases:
    Spain
  • Study on Reducing Antiplatelet Therapy in Patients with Acute Coronary Syndrome and High Bleeding Risk Using Prasugrel, Ticagrelor, or Clopidogrel

    Recruiting

    1 1 1 1
    Investigated diseases:
    Italy
  • Study on Personalized Antithrombotic Therapy with Acenocoumarol, Phenprocoumon, and Apixaban for Patients with Aortic Valve Stenosis Post-TAVI

    Recruiting

    1 1 1 1
    Investigated diseases:
    Belgium Denmark France Germany The Netherlands
  • Study Comparing Drug-Coated Balloon and Drug-Eluting Stents in Patients with Coronary Artery Disease at High Risk of Bleeding Using Acetylsalicylic Acid and Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Finland France Spain
  • Study on Ticagrelor and Aspirin for Patients with Severe Aortic Stenosis After Heart Valve Replacement

    Recruiting

    1 1 1 1
    Investigated diseases:
    Italy Portugal Spain
  • Study on Reducing Bleeding Risk in Heart Attack Patients Using Clopidogrel, Ticagrelor, and Prasugrel After Stent Procedure

    Recruiting

    1 1 1 1
    Investigated diseases:
    Denmark

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Acute Coronary Syndrome: A group of conditions that suddenly reduce blood flow to the heart, including unstable angina and heart attacks.
  • Percutaneous Coronary Intervention: A non-surgical procedure used to open blocked coronary arteries, often involving the placement of a stent.
  • Platelet Inhibition: The process of preventing platelets (blood cells involved in clotting) from sticking together and forming clots.
  • Bioequivalence: The property of two drugs having the same active ingredient and producing the same biological effects when given in the same dose.
  • Major Adverse Cardiovascular Events (MACE): A composite outcome in clinical trials that typically includes events such as death, heart attack, and stroke.
  • Renal Impairment: A condition where the kidneys are not functioning properly, which can affect how drugs are processed and eliminated from the body.
  • Loading Dose: A higher initial dose of a medication given to quickly achieve therapeutic levels in the body.
  • Maintenance Dose: The amount of a medication given to maintain therapeutic levels in the body after the initial loading dose.

References

  1. https://clinicaltrials.gov/study/NCT03708588
  2. https://clinicaltrials.gov/study/NCT05474053
  3. https://clinicaltrials.gov/study/NCT01543932
  4. https://clinicaltrials.gov/study/NCT00721448
  5. https://clinicaltrials.gov/study/NCT02022748
  6. https://clinicaltrials.gov/study/NCT03354429
  7. https://clinicaltrials.gov/study/NCT02521038